Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
VPG Stock: Analyst Targets Point to +45% Upside Potential

VPG Stock: Analyst Targets Point to +45% Upside Potential

Key Takeaways

  • The central $74 target represents the arithmetic mean of three current analyst price targets, roughly 45% above the latest closing price near $50.90.
  • Verified targets range from $61 (Sidoti) to $87 (Lake Street), with B. Riley at $75, producing a mean of about $74.33, rounded to $74.
  • All three covering firms maintain constructive ratings on the shares, even after trimming targets following the fiscal third-quarter report.
  • Key supporting elements include an eight-quarter streak of book-to-bill above 1.0, a substantial backlog, a net-cash balance sheet, and exposure to defense, semiconductor, and humanoid-robotics demand.
  • Primary risks center on thin GAAP profitability, ongoing margin pressure, and guidance that has fallen short of consensus expectations.
  • For updates on developments, check the Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Price Targets and Consensus View

VPG is a New York Stock Exchange-listed producer of precision sensors and measurement systems for stress, force, weight, and pressure applications, with operations divided across Sensors, Weighing Solutions, and Measurement Systems segments. Following the company's fiscal third-quarter 2026 earnings, three analyst price targets remain active. Sidoti reduced its target to $61 from $77, B. Riley lowered its to $75 from $105 while retaining a Buy rating, and Lake Street trimmed its to $87 from $98 while keeping a Buy. The arithmetic mean of these targets comes to about $74.33, which rounds to a $74 central target, with the range spanning $61 to $87.

The broad spread highlights differing views on the pace of profit-margin recovery. The lower end accounts for continued margin compression, whereas the higher end incorporates the company's 2028 goals for 8%-10% organic growth and gross margins in the 46.5%-47.5% range, compared with 39.2% in 2025. The $74 level is simply a calculated average of the individual targets rather than an official consensus figure.

Current Market Position and Path Toward the Target

With shares closing near $50.90 on November 13, 2026, a move to $74 would represent a gain of roughly 45%, which is a meaningful advance. The stock's 52-week range of $29.08 to $151.78 illustrates its volatility, as shares climbed to a high near $152 in mid-2026 before a sharp pullback that included a double-digit drop around the earnings release and briefly touched near $41.

The shares now sit below both the 50-day and 200-day moving averages, near $62 and $74 respectively, so the target aligns with the 200-day average and the $75 round-number area. Trailing P/E is not meaningful given a small GAAP loss on a trailing basis, and the stock trades near 29 times trailing EBITDA. Reaching $74 would likely require confirmation that the current re-rating has run its course and that earnings are starting to turn higher.

What Could Support a Move Toward the Target

The constructive case centers on demand momentum. VPG posted record quarterly orders and a book-to-bill ratio above 1.0 for an eighth straight quarter, with backlog near $151 million. Management highlighted secular tailwinds in semiconductors and AI infrastructure, data centers, defense, and humanoid robotics, where revenue of roughly $4 million in 2025 is expected to expand about 50% annually through 2028. The balance sheet provides support with net cash of roughly $65 million, or about $4.88 per share, and minimal debt. Analysts also reference new-business development and a projected multi-year improvement in profitability as reasons their targets sit well above the current price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Prevent the Target From Being Reached

The main hurdle remains profitability. Third-quarter adjusted EPS of $0.14 missed the roughly $0.15 consensus and came in well below $0.26 a year earlier, while GAAP net income was near breakeven. Fourth-quarter revenue guidance of $84-$91 million had a midpoint below consensus, and management noted currency, tariffs, bonus accruals, and higher headcount as margin headwinds. Sidoti, for instance, reduced its 2026, 2027, and 2028 EPS estimates while lowering its target. A further margin shortfall, a reversal in the bookings trend, or an extended valuation reset could keep the shares below $74.

Technical Levels and Market Structure

The recent low near $41, established during the post-earnings selloff, serves as the nearest major support, with the $40 psychological level just beneath. Resistance begins around the 50-day moving average near $62, followed by the $74-$75 zone that coincides with the 200-day average. The prior peak near $151.78 lies well above current levels and is not a practical near-term benchmark. The stock's position below both major moving averages signals a broken longer-term uptrend that would need repair for a sustained advance.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect an approximate 12-month research horizon, though firms do not always specify one explicitly. The next earnings report is expected around February 2027. Investors should track the book-to-bill ratio, backlog conversion, gross and operating margins, full-year 2027 revenue guidance, progress on humanoid-robotics and new-business programs, and any additional analyst target revisions. Macroeconomic factors such as interest-rate policy and semiconductor demand also influence this cyclical, capital-spending-sensitive business.

AI Daily Buy/Sell Signals

In my own research process, I frequently rely on Tickeron's AI Daily Buy/Sell Signals to monitor stocks like VPG. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and data-driven analysis. It helps surface opportunities, track existing holdings, and identify trend changes more efficiently than manual review alone. For anyone following VPG's price action, this offers a structured way to stay updated on evolving technical conditions.

Final Assessment

The $74 central target, derived from three current analyst estimates, points to a roughly 45% advance from the latest price near $50.90. Support stems from strengthening bookings, a solid balance sheet, and long-term secular exposure, while thin current earnings, margin pressure, and below-consensus guidance represent the chief obstacles. The wide $61-to-$87 target range underscores that even bullish analysts differ on the speed of profitability recovery. Whether VPG reaches $74 will likely depend on management's ability to translate backlog and new-business momentum into visible earnings growth over the coming quarters, an outcome that remains uncertain rather than assured.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VPG

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


VPG in -5.42% downward trend, declining for three consecutive days on November 13, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VPG declined for three days, in 210 of 289 cases, the price declined further within the following month. The odds of a continued downward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VPG as a result. In 66 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

VPG moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for VPG crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.

The Aroon Indicator for VPG entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VPG's RSI Indicator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 61 cases where VPG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Moving Average Convergence Divergence (MACD) for VPG just turned positive on November 12, 2026. Looking at past instances where VPG's MACD turned positive, the stock continued to rise in 35 of 52 cases over the following month. The odds of a continued upward trend are 67%.

Following a +10.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where VPG advanced for three days, in 191 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

VPG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. VPG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.770) is normal, around the industry mean (1.448). VPG has a moderately high P/E Ratio (147.367) as compared to the industry average of (5.350). Projected Growth (PEG Ratio) (1.753) is also within normal values, averaging (5.470). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (2.475) is also within normal values, averaging (32.028).

Industry description

This industry manufactures electronic products used in various critical and sophisticated technologies, including laser-based systems, circuit and continuity testers, electro-optical measuring instruments and high-speed precision weighing and inspection equipment. Some major companies operating in this business are Canon Inc., Keysight Technologies Inc., and Fortive Corp.

Market Cap

The average market capitalization across the Electronic Equipment/Instruments Industry is 7.99B. The market cap for tickers in the group ranges from 12.56K to 120.89B. KYCCF holds the highest valuation in this group at 120.89B. The lowest valued company is FLXT at 12.56K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Equipment/Instruments Industry was 5%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -13%. FCUV experienced the highest price growth at 130%, while ARAI experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the Electronic Equipment/Instruments Industry was 87%. For the same stocks of the Industry, the average monthly volume growth was 232% and the average quarterly volume growth was 107%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 50
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 81
Seasonality Score: 6 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of foil technology products

Industry ElectronicEquipmentInstruments

Industry
Electronic Components
Address
851 Duportail Road
Phone
+1 484 321-5300
Employees
2100
Web
https://www.vpgsensors.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
Lead catalyst: Chemomab has secured alignment with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a single Phase 3 registration trial for nebokitug in primary sclerosing cholangitis (PSC), a rare liver disease with no approved disease-modifying therapy. Strategic pivot: A planned merger with Scipher Medicine is expected to close by year-end 2026, extending nebokitug into an AI-powered, precision-medicine Phase 2 trial in rheumatoid arthritis (RA).